Evidence map›Paper›PMID 42760941›Full record

ArticleFrontiers in pharmacology2026

Hong Cao, Jieru Wu, Yuan Yuan, Jing Li, Wenling Feng, Aliye Baierdi, Muyun Li, Yubo Wang, Jun Zhao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hong Cao *State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Jieru Wu *Department of Pharmacy, Xinjiang Autonomous Region Hospital of Traditional Chinese Medicine, Urumqi, China.
Yuan YuanState Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Jing LiState Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Wenling FengState Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Aliye BaierdiDepartment of Pharmacy, Kashgar Prefecture Traditional Chinese Medicine Hospital, Kashgar, China.
Muyun LiSchool of Pharmacy, Xinjiang Medical University, Urumqi, China.
Yubo WangState Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Jun ZhaoState Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: H-type hypertension, defined as primary hypertension combined with elevated plasma homocysteine (Hcy) ≥10 μmol/L, represents the predominant hypertensive phenotype in China. Although current guidelines recommend folic acid (FA) supplementation alongside antihypertensive therapy, a substantial treatment gap persists in routine clinical practice. The Methods: We conducted a single-centre, retrospective cohort study of 660 H-type hypertensive patients who received guideline-compliant antihypertensive therapy but no FA supplementation, enrolled from a tertiary hospital in Xinjiang, China (January 2019-December 2022). The primary outcome was BP control at follow-up (systolic BP < 140 mmHg and diastolic BP < 90 mmHg). Given the known dosage effect of Results: The overall BP control rate was 61.5% (406/660). Conclusion: In H-type hypertensive patients not receiving FA supplementation, the

Indexed as

blood pressure controlfolic acidhomocysteineH-type hypertensionmethylenetetrahydrofolate reductaseMTHFR C677T polymorphismreal-world dataretrospective cohort study

Identifiers

PMID42760941
PMCPMC13585575

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.